✦ LIBER ✦

Approach to the treatment of cutaneous malignancy in HIV-infected patients

✍ Scribed by Karl Wilkins; Jacqueline C. Dolev; Ryan Turner; Philip E. LeBoit; Timothy G. Berger; Toby A. Maurer

Book ID: 109115780
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 101 KB
Volume: 18
Category: Article
ISSN: 1396-0296
DOI: 10.1111/j.1529-8019.2005.05003.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adherence to treatment in Swedish HIV-in

Adherence to treatment in Swedish HIV-infected patients

✍ B. Södergård; M. Halvarsson; M. P. Tully; S. Mindouri; M.-L. Nordström; S. Lindb 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

Comparative study of cutaneous leishmani

Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana

✍ P. Couppié; E. Clyti; M. Sobesky; F. Bissuel; P. Del Giudice; D. Sainte-Marie; J 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB

Cutaneous effects of highly active antir

Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients

✍ Heidi H. Kong; Sarah A. Myers 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

Considerations in the approach to invasi

Considerations in the approach to invasive fungal infection in patients with haematological malignancies

✍ Eric J. Bow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

Hematopoietic growth factors in the trea

Hematopoietic growth factors in the treatment of patients with HIV infection

✍ Ronald T. Mitsuyasu 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 1023 KB

Approach to Dyslipidemia, Lipodystrophy,

Approach to Dyslipidemia, Lipodystrophy, and Cardiovascular Risk in Patients with HIV Infection

✍ J. Gregory Troll 📂 Article 📅 2010 🏛 Current Science Inc. 🌐 English ⚖ 130 KB

There is a significant prevalence (20%–80% depending on the population and the study) of lipid disorders and other cardiovascular risk factors in people living with HIV infection. This review focuses on HIV and HIV treatment–associated metabolic and cardiovascular concerns, including dyslipidemias,